EDX Medical expands testicular cancer diagnostics

EDX Medical Group PLC, based in Cambridge, England, has announced a new step forward in the fight against testicular cancer by signing an exclusive agreement with mirdetect GmbH. This partnership allows EDX to distribute the innovative M371 blood test, which identifies critical biomarkers for early-stage testicular cancer, a prevalent condition among young men. The distribution will cover the UK, Sweden, Finland, Norway, and Denmark.

The M371 test aligns with EDX Medical’s mission to deliver digital diagnostic solutions targeting cancer, heart disease, and infectious diseases. By offering a tool for early detection, the test empowers healthcare professionals to make personalised and optimised treatment decisions, enhancing patient outcomes.

Expressing enthusiasm for the partnership, Chief Executive Officer Mike Hudson noted the synergy between the test and EDX’s existing diagnostics portfolio. He also highlighted plans to collaborate with mirdetect further, aiming to improve the test and associated services for broader healthcare benefits.

This agreement underscores EDX Medical’s commitment to advancing accessible, precise diagnostics that support better patient care.

EDX Medical Group Plc (AQSE:EDX) is a global specialist in digital clinical diagnostics; developing and supporting high-performance products and services to provide cost-effective prediction of disease risk, inform clinical decision-making, enable personalised healthcare and accelerate the development of new medicines for cancer, neurology, heart disease and infectious diseases.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn
EDX Medical Group plc

More articles like this

EDX Medical Group plc

Innovative testing for testicular cancer detection

With the Movember campaign gaining momentum, it’s an opportune time to address testicular cancer, a condition that disproportionately affects young men. Each year in Europe, over 25,000 new cases are diagnosed, making it the most prevalent

EDX Medical Group plc

EDX Medical secures exclusive deal for testicular cancer test

EDX Medical announced a new partnership, securing exclusive rights to distribute mirdetect GmbH’s M371 diagnostic test for testicular cancer. This Cambridge-based company is known for its innovative digital diagnostic tools, which target critical health issues, including

EDX Medical Group plc

Genetic testing’s role in identifying cancer risk

Cancer remains a significant global health issue and is the second leading cause of death in the U.S., following heart disease. While many cancers are linked to lifestyle, environmental, or unknown factors, some are hereditary, resulting

EDX Medical Group plc

Understanding genes and genetic variants for cancer risk

Genes are sections of DNA that carry instructions for building proteins, essential for the body’s proper functioning. Changes in these genes are known as single-gene variants. Genetic testing can reveal different types of gene variants, including

EDX Medical Group plc

New blood test predicts colorectal cancer recurrence

The Guardant Reveal liquid biopsy test has shown potential in predicting disease recurrence in patients with stage II and higher colorectal cancer (CRC), based on data from the COSMOS study, which has been published in Clinical

EDX Medical Group plc

The role of genetics in cancer risk

While cancer itself is not directly inherited, the genes passed down from your parents can influence your likelihood of developing certain cancers. In some families, cancer appears to be more common due to shared risk factors,

EDX Medical Group plc

Liquid biopsy in cancer detection and treatment

Recent years have seen liquid biopsy making significant strides in the healthcare landscape, especially for cancer detection. Known also as multi-cancer detection (MCD) or MCD assays, this test screens for various cancers using just a blood

EDX Medical Group plc

EDX Medical Chairman and Founder provide shareholder update

EDX Medical Group plc (AQSE:EDX), which develops innovative digital diagnostic products and services for the personalised treatment for cancer, heart disease and infectious diseases, has announced that Jason Holt, Chairman of the Company, and Prof. Sir Chris Evans, Founder

EDX Medical Group plc

EDX Medical signs distribution agreement with Caris Life Sciences

EDX Medical Group plc (AQSE:EDX), which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, has announced it has signed a distribution agreement with Caris Life Sciences® (Caris), a leading US-based next-generation